HomeFinanceModerna chief predicts existing vaccines will struggle with Omicron

Moderna chief predicts existing vaccines will struggle with Omicron

The chief executive of Moderna has predicted that existing vaccines will be much less effective at tackling Omicron than earlier strains of Covid-19 and warned it would take months before pharmaceutical companies can manufacture new variant-specific jabs at scale.

Stéphane Bancel said the high number of Omicron mutations on the spike protein, which the virus uses to infect human cells, and the rapid spread of the variant in South Africa, suggested the current crop of vaccines may need to be modified next year.

“There is no world, I think, where [the effectiveness] is the same level . . . we had with Delta,” Bancel told the Financial Times in an interview at the company’s headquarters in Cambridge, Massachusetts.

He added: “I think it’s going to be a material drop. I just don’t know how much because we need to wait for the data. But all the scientists I’ve talked to . . . are like ‘this is not going to be good’.”

The Moderna chief executive’s comments come as other public health experts and politicians have tried to strike a more upbeat tone about the ability of existing vaccines to confer protection against Omicron.

Joe Biden, US president, subsequently said Omicron was “a cause for concern, not a cause for panic,” adding that the government’s medical experts “believe that the vaccines will continue to provide a degree of protection against severe disease”.

However, Bancel said scientists were worried because 32 of the 50 mutations in the Omicron variant are on the spike protein, which the current vaccines focus on to boost the human body’s immune system to combat Covid-19.

Most experts thought such a highly mutated variant would not emerge for another one or two years, Bancel added.

Bancel’s predictions rattled investors in Asia, with equities and stock futures dropping and crude prices losing ground.

In Japan, the benchmark Nikkei 225 index swung to a loss of as much as 1.1 per cent following the FT report. Hong Kong’s Hang Seng index was 2.3 per cent lower. S&P 500 futures erased initial gains to tip US stocks to drop almost 1 per cent, while FTSE 100 was set to shed 1.2 per cent at the open in London.

Concerns over the variant drove traders to seek safety in bonds, pushing the yield on 10-year US Treasuries down 0.05 percentage points, while in commodities markets Brent crude, the international oil benchmark, reversed course to be down almost 2 per cent at $72.04 a barrel.

Moderna and Pfizer have become the vaccine suppliers of choice for most of the developed world due to the high effectiveness of their jabs, which are based on messenger RNA (mRNA) technology.

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular